Top Page
Nuchev Pty Ltd
(Sydney:NUC)
Nuchev Pty Ltd (NUC) vs. iShares MSCI Australia ETF (EWA)
Nuchev Pty Ltd Business Overview & Revenue Model
Nuchev Pty Ltd Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.34M | 8.79M | 9.72M | 10.90M | 17.76M |
| Gross Profit | 3.63M | 1.66M | 2.78M | 3.20M | 5.64M |
| EBITDA | -7.18M | -8.57M | -10.88M | -12.40M | -10.09M |
| Net Income | -7.32M | -8.81M | -11.81M | -13.74M | -12.40M |
Balance Sheet | |||||
| Total Assets | 20.09M | 15.32M | 17.75M | 28.31M | 27.51M |
| Cash, Cash Equivalents and Short-Term Investments | 7.61M | 7.49M | 5.13M | 14.53M | 9.44M |
| Total Debt | 322.85K | 284.14K | 154.12K | 286.33K | 386.26K |
| Total Liabilities | 5.34M | 2.51M | 1.92M | 1.62M | 2.23M |
| Stockholders Equity | 14.75M | 12.82M | 15.83M | 26.69M | 25.28M |
Cash Flow | |||||
| Free Cash Flow | -3.74M | -3.38M | -11.62M | -9.86M | -10.76M |
| Operating Cash Flow | -3.73M | -3.26M | -11.61M | -9.49M | -10.69M |
| Investing Cash Flow | -2.19M | -126.83K | -914.20K | 411.90K | -53.94K |
| Financing Cash Flow | 6.06M | 5.78M | -118.28K | 14.16M | 9.88M |
Nuchev Pty Ltd Technical Analysis
Nuchev Pty Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | £7.66B | 7.11 | 6.21% | 3.55% | 1.45% | 25.11% | |
48 Neutral | AU$27.23M | ― | -47.74% | ― | 43.14% | 51.35% | |
47 Neutral | AU$21.25M | ― | -33.40% | ― | -13.09% | -139.06% | |
46 Neutral | €29.73M | ― | -23.00% | ― | -2.14% | 11.40% | |
41 Neutral | AU$15.93M | ― | -240.42% | ― | 14.41% | 76.26% | |
40 Underperform | AU$40.18M | ― | ― | 4.22% | -199.40% |
Nuchev Pty Ltd Corporate Events
Nuchev Limited has issued 8,749,000 fully paid ordinary shares without disclosure to investors, in compliance with the Corporations Act 2001. The company confirms adherence to its reporting and disclosure obligations, with no excluded information requiring disclosure. This move reflects Nuchev’s ongoing commitment to transparency and regulatory compliance, potentially impacting its market operations and stakeholder confidence.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the issuance of 8,749,000 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) as of July 30, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase liquidity in its shares, reflecting its ongoing efforts to strengthen its financial standing and operational capabilities.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Pty Ltd has announced the issuance of 164,532 ordinary fully paid securities, which will be quoted on the ASX as of July 29, 2025. This move is part of the company’s strategy to enhance its financial flexibility and potentially expand its market presence, which could have significant implications for its stakeholders and market positioning.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the issuance of 2,327,678 unquoted securities, specifically options expiring on July 30, 2025, with an exercise price of $0.30. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX, which may impact the company’s financial strategy and stakeholder interests.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited announced that H&S Group has exercised Tranche 2 of their Performance Options, resulting in the issuance of 8,749,000 Fully Paid Ordinary Shares to H&S Investments. This move increases H&S’s shareholding in Nuchev from 45.56% to 48.62% and provides Nuchev with $1.9 million, enhancing its financial flexibility to pursue medium-term strategies. The company’s CEO, Nathan Cheong, expressed appreciation for H&S Group’s support, which aligns with Nuchev’s strategic growth objectives.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Pty Ltd reported a record quarterly revenue of $6.3 million for Q4 FY25, marking a 167% increase from the previous corresponding period. The company’s expansion into the Vietnamese market and a new Sales Agency Agreement with Brauer Natural Medicines and H&S Brand Corporation have been pivotal in driving growth. Oli6® Nutritional sales, particularly in the ANZ and China CBEC markets, have shown significant increases, with the brand outperforming the overall infant formula market. The company aims to achieve breakeven through continued market expansion and strategic partnerships.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited announced the issuance of 333,333 fully paid ordinary shares without disclosure to investors, in compliance with the Corporations Act 2001. This move indicates Nuchev’s adherence to regulatory obligations and its strategic financial maneuvering, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the application for the quotation of 333,333 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 3, 2025. This move involves the issuance, transfer, or reclassification of securities resulting from options being exercised or other convertible securities being converted, reflecting the company’s strategic financial maneuvers to potentially enhance its market presence and shareholder value.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited announced that H&S Group has achieved its second-year performance hurdle under their distribution agreement, leading to the vesting of Tranche 2 performance options. This achievement allows Nuchev to issue up to 8,749,000 shares to H&S Investments, potentially injecting $1.9 million into the company. This capital boost will enhance Nuchev’s financial flexibility, supporting its strategic growth plans. The company appreciates H&S Group’s continued support, which aligns with Nuchev’s objectives for expansion.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the cessation of 705,586 share rights due to the lapse of conditional rights that were not satisfied. This development may affect the company’s issued capital and could have implications for its stakeholders, as it reflects on the company’s current operational conditions and market positioning.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Ltd has announced the appointment of Meng Zhang, also known as Leo, as a new director effective from May 26, 2025. The initial director’s interest notice indicates that Meng Zhang currently holds no securities in the company, either as a registered holder or otherwise, and has no interests in any contracts related to the company. This appointment reflects a strategic decision by Nuchev Ltd, potentially impacting its governance and future direction.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has appointed Meng Zhang, known as Leo, as a Non-Executive Director to its Board. Leo Zhang brings over a decade of cross-border experience in brand management, international trade, and corporate governance, with a strong background in the Asia-Pacific consumer goods market. His leadership at H&S Global Brand Center has been instrumental in the success of several brands in China’s cross-border e-commerce sector and Southeast Asia. This appointment is expected to enhance Nuchev’s board skills and experience, supporting the company’s growth ambitions and recent strategic initiatives, including the acquisition of the bWellness business and partnerships with Brauer and H&S Brands.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.